ARTICLE | Company News
Nabi, GlaxoSmithKline deal
August 10, 2009 7:00 AM UTC
GlaxoSmithKline will acquire Nabi's PentaStaph pentavalent Staphylococcus aureus vaccine program and related assets for $20 million up front and $26 million in milestones. PentaStaph is a preclinical...